Skip to main navigation
  • About
    • Who We Are
    • Core Values
    • Leadership
    • Partners
    • Intellia’s Journey
  • Our Science
    • What is CRISPR?
    • CRISPR Videos
    • Full-Spectrum Approach
    • Scientific Publications & Presentations
    • Glossary
  • Programs & Pipelines
    • Pipeline
    • Clinical Trials
  • Patient Stories
    • Patient Stories
    • Disease Focus
      • Overview
      • Transthyretin Amyloidosis
      • Hereditary Angioedema
      • Alpha-1 Antitrypsin Deficiency
      • Hodgkin Lymphoma
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications & Presentations
    • Corporate Deck
    • Events & Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
  • Full-Spectrum Blog
  • Contact
logo
  • Full-Spectrum Blog
  • Contact
  • About
    • Who We Are
    • Core Values
    • Leadership
    • Partners
    • Intellia’s Journey
  • Our Science
    • What is CRISPR?
    • CRISPR Videos
    • Full-Spectrum Approach
    • Scientific Publications &
      Presentations
    • Glossary
  • Programs & Pipelines
    • Pipeline
    • Clinical Trials
  • Patient Focus
    • Patient Stories
    • Disease Focus
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications &
      Presentations
    • Corporate Deck
    • Events &
      Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
Investors & Media

4

Investor Relations

  • Overview
  • Press Releases
  • Scientific Publications & Presentations
  • Corporate Deck
  • Events & Presentations
  • Press Kit
  • Corporate Governance
  • Financial Info
  • Stock Info
  • Analyst Coverage
  • Investor Resources

SEC Filing Details

Document Details

Form
4
Filing Date
Jun 16, 2022
Document Date
Jun 16, 2022
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Intellia Therapeutics
Issuer
Intellia Therapeutics, Inc.
Filer
DORSA CAROLINE

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
Contact IR Contact IR
Email Alerts
RSS Feeds
RSS Feeds
Print Page

Footer Links

  • Cookie Policy
  • Terms of Use
  • Privacy Policy

© Intellia Therapeutics, Inc. 2023

Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.